What was HJ Science Co., Ltd. Class H’s price range in the past 12 months?
HJ Science Co., Ltd. Class H lowest stock price was HK$24.50 and its highest was HK$82.00 in the past 12 months.
What is HJ Science Co., Ltd. Class H’s market cap?
HJ Science Co., Ltd. Class H’s market cap is HK$1.95B.
When is HJ Science Co., Ltd. Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were HJ Science Co., Ltd. Class H’s earnings last quarter?
HJ Science Co., Ltd. Class H released its earnings results on Aug 28, 2026. The company reported -HK$1.382 earnings per share for the quarter.
Is HJ Science Co., Ltd. Class H overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does HJ Science Co., Ltd. Class H pay dividends?
HJ Science Co., Ltd. Class H does not currently pay dividends.
What is HJ Science Co., Ltd. Class H’s EPS estimate?
HJ Science Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does HJ Science Co., Ltd. Class H have?
HJ Science Co., Ltd. Class H has 73,599,600 shares outstanding.
What happened to HJ Science Co., Ltd. Class H’s price movement after its last earnings report?
HJ Science Co., Ltd. Class H reported an EPS of -HK$1.382 in its last earnings report. Following the earnings report the stock price went up 0.592%.
Which hedge fund is a major shareholder of HJ Science Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6132
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HJ Science Co., Ltd. is a clinical stage biotech company, which engages in research and development of small molecule drugs for tumors, autoimmune & metabolic system diseases for clinical treatments. It provides drug design, in vivo and in vitro activity evaluation, drug metabolism, synthesis, quality research, formulation development, and scale-up. Its products include HJ787, HJ178 and HJ891. The company was founded by Ji Jianxin on February 20, 2017 and is headquartered in Chengdu, China.
Sector
General
Industry
Biotechnology
CEO
Jian Xin Ji
Employees
113
Website
www.hj3h.com
Address
No. 501,Building 4, Chengdu, SI, 610000, CN
HJ Science Co., Ltd. Class H (6132) Earnings & Revenues